Denosumab and Teriparatide

Mechanism

Pharmacological Class and Group

Human anti-RANKL monoclonal antibody (Denosumab) and Recombinant analogue of human parathyroid hormone (PTH 1-34) with direct osteoblastic anabolic effect (Teriparatide).

Mechanism of Action

Both biological agents modulate the physiological cascade of bone remodeling through two opposite and complementary pharmacological targets:

• Denosumab: IgG2 isotype monoclonal antibody designed with specific affinity to bind to receptor activator of nuclear factor kappa B ligand (RANKL). RANKL is secreted by osteoblasts and osteocytes and its binding to the RANK receptor in preosteoclasts is mandatory for their viability.
• Teriparatide: Recombinant active fragment of the first 34 amino-terminal amino acids of native PTH. It acts as a high-potency agonist of the parathyroid hormone type 1 G protein-coupled receptor (PTHR1).

Mechanism of Denosumab (Potent Anti-Resorptive)

1. Blocking the RANK-RANKL junction: Denosumab physiologically mimics endogenous osteoprotegerin (OPG):

Denosumab RANKL Blockade of the RANK Receptor in preosteoclasts

2. Suppression of Osteoclastogenesis: By preventing the activation of the RANK receptor, the differentiation, maturation and survival of active osteoclasts is blocked, immediately and massively decreasing serum markers of bone resorption.

Mechanism of Teriparatide (True Anabolic)

1. Pulsatile Intermittent Administration: The single daily injection induces brief plasma peaks of PTHR1 that activate anabolic intracellular pathways through coupling to protein Gs/adenylate cyclase and Gq/phospholipase C.

2. Direct Osteoblastic Stimulation: Promotes the differentiation of preosteoblasts to active mature osteoblasts, decreases osteoblastic apoptosis and terminally blocks the transcription of the protein sclerostin by osteocytes. This causes de novo bone formation greater than bone resorption (widening the trabecular and cortical space of the femur and spine).

Pharmacokinetics

High Resolution Pharmacokinetics

• Denosumab (Prolia): Exclusive subcutaneous administration. Bioavailability of 62%. Maximum plasma concentration (C_max) achieved 10 days after SC injection. Long elimination half-life of between 25 and 28 days. Systemic clearance through the nonspecific immunoglobulin reticulo-endothelial system (it is not eliminated by the kidney or liver). Its effect persists for 6 months after taking.
• Teriparatide (Forteo): Daily self-injectable subcutaneous administration. High bioavailability (95%). Ultra-rapid absorption and elimination: the maximum peak is reached 30 minutes post-injection and returns to baseline after 3 hours. Metabolism through nonspecific hepatic and renal enzymatic fragmentation. Ultra-short plasma elimination half-life of just 1 hour, an essential profile to avoid the destructive secondary hyperthyroidism of continuous infusion of PTH.

Indicators and dose

Clinical Indications and Off-Label Uses

Indications of Denosumab (Prolia / Xgeva)

• Treatment of postmenopausal and senile osteoporosis with high risk of fractures.
• Loss of bone mass associated with systemic hormonal suppression in men with prostate cancer (androgen blockade) or women with breast cancer (aromatase inhibitors).
• Prevention of tumor bone events in solid bone metastases (Xgeva).

Indications of Teriparatide (Forteo)

• Treatment of severe osteoporosis with previous fragility fractures, failure of usual antiresorptive therapy or in patients at very high risk of fracture.
• Osteoporosis due to chronic glucocorticoids.
• Delayed consolidation of pathological fractures (off-label): Proven clinical acceleration in the formation of stable bone callus.

Dosage and Clinical Adjustment

Denosumab (Prolia):

• Fixed dose of 60 mg administered subcutaneously once every 6 months in the thigh, abdomen, or back of the arm.
• It is essential and mandatory to ensure adequate and constant daily supplementation of calcium (1000 mg) and vitamin D3 (minimum 800-1000 IU) to prevent the appearance of symptomatic hypocalcemia during periods of maximum capillary bone suppression.

Teriparatide (Forteo):

• Dose of 20 µg administered subcutaneously once a day, injected into the abdomen or thigh, using a multidose prefilled autoinjector pen.
• The maximum recommended lifetime treatment duration is 24 continuous months due to the theoretical risk of osteosarcoma demonstrated in murine models with sustained doses for life.

Adjustment in Kidney Failure:

• Denosumab: Does not require dose adjustment in renal dysfunction of any degree (even in terminal stages of dialysis). However, the lower the patient's renal clearance, the greater the risk of severe hypocalcemia, which requires weekly preventive monitoring and optimal supplementation with calcitriol.
• Teriparatide: Use with extreme caution if eGFR is < 30 mL/min/1.73 m² due to altered plasma clearance of the active peptide fragment. Contraindicated in dialysis.

Security

Absolute and Relative Contraindications

Contraindications of Denosumab

• Hypersensitivity to monoclonal antibody.
• Severe uncorrected hypocalcemia: The massive blockage of bone resorption prevents the mobilization of calcium from the bone to the capillary circulation, potentially inducing crises of severe lethal hypocalcemia, especially in advanced kidney disease.

Contraindications of Teriparatide

• Patients at high risk for osteosarcoma: Active Paget's bone disease, unexplained idiopathic elevation of bone alkaline phosphatase, history of previous skeletal radiotherapy to the skeleton.
• Previous episodes of hypercalcemia.
• Cancers of bone origin or active skeletal metastases.

Adverse Effects (ADR) and Specific Toxicity

• Denosumab (Common 1%-10%): Pain in upper/lower extremities, deep sciatica, dry dermal eczema, flatulence, increased clinical susceptibility to skin and soft tissue infections (erythematous cellulitis, due to the role of the RANKL receptor in the local modulation of immunological T lymphocytes).
• Denosumab (Rare): Severe symptomatic hypocalcemia (critical AMR mediated by blockage of bone reservoir clearance), osteonecrosis of the jaw (ONJ) in high monthly oncological regimens, and Rebound Phenomenon of Multiple Vertebral Fractures after discontinuation planned drug.
• Teriparatide (Common 1%-10%): Transient nausea, abdominal cramping pain, throbbing headache, painful muscle cramps in the lower limbs, transient orthostatic hypotension in the first 30 minutes after initial injections, mild transient dose-dependent hypercalcemia (short-duration self-limiting spikes).

Critical Alert: The Rebound Effect after Denosumab Withdrawal

Unlike bisphosphonates (which are retained in the bone matrix for decades), the antiresorptive effects of denosumab completely cease once the antibody is cleared from the capillary circulation at the sixth month after injection. When the competitive blockade of RANKL disappears, a phenomenon of accelerated and massive recruitment of hyperactive de novo osteoclasts occurs. This triggers massive rebound accelerated bone resorption:

Denosumab cessation Explosive increase in resorption markers (CTX-1) Rapid loss of BMD Multiple Vertebral Fractures

Patients may experience cascading multiple vertebral crush fractures within 3 to 12 months after delaying or stopping a dose of denosumab. The administration of denosumab should never be suspended without immediately and as a priority establishing sequential transitional therapy with an antiresorptive agent with bone retention, such as intravenous zoledronic acid, administered 6 months after the last dose of denosumab.

Drug Interactions of Clinical Relevance

• Calcitriol or active vitamin D analogues: Hypercalcemic synergism with teriparatide. Requires close monitoring of 24-hour urinary calcium excretion to prevent severe nephrolithiasis.
• Biological immunosuppressants (Infliximab, Adalimumab) or systemic: Concomitant use with denosumab may increase the risk of severe opportunistic skin infections.

Safety in Pregnancy and Breastfeeding

• Pregnancy: Contraindicated in pregnancy. Denosumab may alter fetal bone immune development and cause embryonic death according to animal studies. Teriparatide lacks adequate studies in humans, avoid.
• Breastfeeding: Not recommended during this period.